<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32403313</PMID><DateCompleted><Year>2021</Year><Month>03</Month><Day>15</Day></DateCompleted><DateRevised><Year>2021</Year><Month>03</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4425</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>5</Issue><PubDate><Year>2020</Year><Month>May</Month><Day>11</Day></PubDate></JournalIssue><Title>Genes</Title><ISOAbbreviation>Genes (Basel)</ISOAbbreviation></Journal><ArticleTitle>Metabolomics: A Tool to Understand the Impact of Genetic Mutations in Amyotrophic Lateral Sclerosis.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">537</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/genes11050537</ELocationID><Abstract><AbstractText>Metabolomics studies performed in patients with amyotrophic lateral sclerosis (ALS) reveal a set of distinct metabolites that can shed light on the pathological alterations taking place in each individual. Metabolites levels are influenced by disease status, and genetics play an important role both in familial and sporadic ALS cases. Metabolomics analysis helps to unravel the differential impact of the most common ALS-linked genetic mutations (as <i>C9ORF72</i>, <i>SOD1</i>, <i>TARDBP,</i> and <i>FUS</i>) in specific signaling pathways. Further, studies performed in genetic models of ALS reinforce the role of TDP-43 pathology in the vast majority of ALS cases. Studies performed in differentiated cells from ALS-iPSC (induced Pluripotent Stem Cells) reveal alterations in the cell metabolism that are also found in ALS models and ultimately in ALS patients. The development of metabolomics approaches in iPSC derived from ALS patients allow addressing and ultimately understanding the pathological mechanisms taking place in any patient. Lately, the creation of a "patient in a dish" will help to identify patients that may benefit from specific treatments and allow the implementation of personalized medicine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lanznaster</LastName><ForeName>D&#xe9;bora</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-5911-3120</Identifier><AffiliationInfo><Affiliation>UMR 1253, iBrain, University of Tours, Inserm, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Veyrat-Durebex</LastName><ForeName>Charlotte</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>UMR 1253, iBrain, University of Tours, Inserm, 37000 Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU de Tours, Service de Biochimie et Biologie Mol&#xe9;culaire, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vourc'h</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>UMR 1253, iBrain, University of Tours, Inserm, 37000 Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU de Tours, Service de Biochimie et Biologie Mol&#xe9;culaire, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andres</LastName><ForeName>Christian R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>UMR 1253, iBrain, University of Tours, Inserm, 37000 Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU de Tours, Service de Biochimie et Biologie Mol&#xe9;culaire, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blasco</LastName><ForeName>H&#xe9;l&#xe8;ne</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>UMR 1253, iBrain, University of Tours, Inserm, 37000 Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU de Tours, Service de Biochimie et Biologie Mol&#xe9;culaire, 37000 Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corcia</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>UMR 1253, iBrain, University of Tours, Inserm, 37000 Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CHU de Tours, Service de Neurologie, 37000 Tours, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>05</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Genes (Basel)</MedlineTA><NlmUniqueID>101551097</NlmUniqueID><ISSNLinking>2073-4425</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000073885">C9orf72 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C568651">C9orf72 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000599550">FUS protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D034702">RNA-Binding Protein FUS</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000606290">SOD1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.15.1.1</RegistryNumber><NameOfSubstance UI="D000072105">Superoxide Dismutase-1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073885" MajorTopicYN="N">C9orf72 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002478" MajorTopicYN="N">Cells, Cultured</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055106" MajorTopicYN="N">Genome-Wide Association Study</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059014" MajorTopicYN="N">High-Throughput Nucleotide Sequencing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057026" MajorTopicYN="N">Induced Pluripotent Stem Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055432" MajorTopicYN="Y">Metabolomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="Y">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057285" MajorTopicYN="N">Precision Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D034702" MajorTopicYN="N">RNA-Binding Protein FUS</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000072105" MajorTopicYN="N">Superoxide Dismutase-1</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ALS</Keyword><Keyword MajorTopicYN="N">genetics</Keyword><Keyword MajorTopicYN="N">iPSC</Keyword><Keyword MajorTopicYN="N">metabolomics</Keyword><Keyword MajorTopicYN="N">personalized medicine</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. </CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>3</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32403313</ArticleId><ArticleId IdType="pmc">PMC7288444</ArticleId><ArticleId IdType="doi">10.3390/genes11050537</ArticleId><ArticleId IdType="pii">genes11050537</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Chio A., Logroscino G., Traynor B.J., Collins J., Simeone J.C., Goldstein L.A., White L.A. Global epidemiology of amyotrophic lateral sclerosis: A systematic review of the published literature. Neuroepidemiology. 2013;41:118&#x2013;130. doi: 10.1159/000351153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000351153</ArticleId><ArticleId IdType="pmc">PMC4049265</ArticleId><ArticleId IdType="pubmed">23860588</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsultan A.A., Waller R., Heath P.R., Kirby J. The genetics of amyotrophic lateral sclerosis: Current insights. Degener. Neurol. Neuromuscul. Dis. 2016;6:49&#x2013;64. doi: 10.2147/DNND.S84956.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/DNND.S84956</ArticleId><ArticleId IdType="pmc">PMC6053097</ArticleId><ArticleId IdType="pubmed">30050368</ArticleId></ArticleIdList></Reference><Reference><Citation>Maurel C., Dangoumau A., Marouillat S., Brulard C., Chami A., Hergesheimer R., Corcia P., Blasco H., Andres C.R., Vourc&#x2019;h P. Causative genes in amyotrophic lateral sclerosis and protein degradation pathways: A link to neurodegeneration. Mol. Neurobiol. 2018;55:6480&#x2013;6499. doi: 10.1007/s12035-017-0856-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-017-0856-0</ArticleId><ArticleId IdType="pubmed">29322304</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Z.Y., Zhou Z.R., Che C.H., Liu C.Y., He R.L., Huang H.P. Genetic epidemiology of amyotrophic lateral sclerosis: A systematic review and meta-analysis. J. Neurol. Neurosurg. Psychiatry. 2017;88:540&#x2013;549. doi: 10.1136/jnnp-2016-315018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2016-315018</ArticleId><ArticleId IdType="pubmed">28057713</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L., Pradat P.F., Ludolph A.C., Loeffler J.P. Energy metabolism in amyotrophic lateral sclerosis. Lancet Neurol. 2011;10:75&#x2013;82. doi: 10.1016/S1474-4422(10)70224-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(10)70224-6</ArticleId><ArticleId IdType="pubmed">21035400</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri A., Coccurello R. What is "Hyper" in the ALS hypermetabolism? Mediat. Inflamm. 2017;2017:7821672. doi: 10.1155/2017/7821672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2017/7821672</ArticleId><ArticleId IdType="pmc">PMC5610793</ArticleId><ArticleId IdType="pubmed">29081604</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyn F.J., Ioannides Z.A., van Eijk R.P.A., Heggie S., Thorpe K.A., Ceslis A., Heshmat S., Henders A.K., Wray N.R., van den Berg L.H., et al. Hypermetabolism in ALS is associated with greater functional decline and shorter survival. J. Neurol. Neurosurg. Psychiatry. 2018;89:1016&#x2013;1023. doi: 10.1136/jnnp-2017-317887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2017-317887</ArticleId><ArticleId IdType="pmc">PMC6166607</ArticleId><ArticleId IdType="pubmed">29706605</ArticleId></ArticleIdList></Reference><Reference><Citation>Jesus P., Fayemendy P., Nicol M., Lautrette G., Sourisseau H., Preux P.M., Desport J.C., Marin B., Couratier P. Hypermetabolism is a deleterious prognostic factor in patients with amyotrophic lateral sclerosis. Eur. J. Neurol. 2018;25:97&#x2013;104. doi: 10.1111/ene.13468.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.13468</ArticleId><ArticleId IdType="pubmed">28940704</ArticleId></ArticleIdList></Reference><Reference><Citation>Brito M.D., da Silva G.F.G., Tilieri E.M., Araujo B.G., Calio M.L., Rosenstock T.R. Metabolic alteration and amyotrophic lateral sclerosis outcome: A systematic review. Front. Neurol. 2019;10:1205. doi: 10.3389/fneur.2019.01205.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.01205</ArticleId><ArticleId IdType="pmc">PMC6879457</ArticleId><ArticleId IdType="pubmed">31824397</ArticleId></ArticleIdList></Reference><Reference><Citation>Boylan K.B., Glass J.D., Crook J.E., Yang C., Thomas C.S., Desaro P., Johnston A., Overstreet K., Kelly C., Polak M., et al. Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in amyotrophic lateral sclerosis. J. Neurol. Neurosurg. Psychiatry. 2013;84:467&#x2013;472. doi: 10.1136/jnnp-2012-303768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp-2012-303768</ArticleId><ArticleId IdType="pubmed">23117489</ArticleId></ArticleIdList></Reference><Reference><Citation>Mejzini R., Flynn L.L., Pitout I.L., Fletcher S., Wilton S.D., Akkari P.A. ALS Genetics, mechanisms, and therapeutics: Where are we now? Front. Mol. Neurosci. 2019;13:1310. doi: 10.3389/fnins.2019.01310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01310</ArticleId><ArticleId IdType="pmc">PMC6909825</ArticleId><ArticleId IdType="pubmed">31866818</ArticleId></ArticleIdList></Reference><Reference><Citation>Manolio T.A., Collins F.S., Cox N.J., Goldstein D.B., Hindorff L.A., Hunter D.J., McCarthy M.I., Ramos E.M., Cardon L.R., Chakravarti A., et al. Finding the missing heritability of complex diseases. Nature. 2009;461:747&#x2013;753. doi: 10.1038/nature08494.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature08494</ArticleId><ArticleId IdType="pmc">PMC2831613</ArticleId><ArticleId IdType="pubmed">19812666</ArticleId></ArticleIdList></Reference><Reference><Citation>DeJesus-Hernandez M., Mackenzie I.R., Boeve B.F., Boxer A.L., Baker M., Rutherford N.J., Nicholson A.M., Finch N.A., Flynn H., Adamson J., et al. Expanded GGGGCC hexanucleotide repeat in noncoding region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron. 2011;72:245&#x2013;256. doi: 10.1016/j.neuron.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3202986</ArticleId><ArticleId IdType="pubmed">21944778</ArticleId></ArticleIdList></Reference><Reference><Citation>Renton A.E., Majounie E., Waite A., Simon-Sanchez J., Rollinson S., Gibbs J.R., Schymick J.C., Laaksovirta H., van Swieten J.C., Myllykangas L., et al. A hexanucleotide repeat expansion in C9ORF72 is the cause of chromosome 9p21-linked ALS-FTD. Neuron. 2011;72:257&#x2013;268. doi: 10.1016/j.neuron.2011.09.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2011.09.010</ArticleId><ArticleId IdType="pmc">PMC3200438</ArticleId><ArticleId IdType="pubmed">21944779</ArticleId></ArticleIdList></Reference><Reference><Citation>Nassif M., Woehlbier U., Manque P.A. The enigmatic role of C9ORF72 in autophagy. Front. Mol. Neurosci. 2017;11:442. doi: 10.3389/fnins.2017.00442.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2017.00442</ArticleId><ArticleId IdType="pmc">PMC5541066</ArticleId><ArticleId IdType="pubmed">28824365</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Wang J. C9orf72-dependent lysosomal functions regulate epigenetic control of autophagy and lipid metabolism. Autophagy. 2019;15:913&#x2013;914. doi: 10.1080/15548627.2019.1580106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15548627.2019.1580106</ArticleId><ArticleId IdType="pmc">PMC6526819</ArticleId><ArticleId IdType="pubmed">30767689</ArticleId></ArticleIdList></Reference><Reference><Citation>Farg M.A., Sundaramoorthy V., Sultana J.M., Yang S., Atkinson R.A., Levina V., Halloran M.A., Gleeson P.A., Blair I.P., Soo K.Y., et al. C9ORF72, implicated in amytrophic lateral sclerosis and frontotemporal dementia, regulates endosomal trafficking. Hum. Mol. Genet. 2014;23:3579&#x2013;3595. doi: 10.1093/hmg/ddu068.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddu068</ArticleId><ArticleId IdType="pmc">PMC4049310</ArticleId><ArticleId IdType="pubmed">24549040</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly C.J., Zhang P.W., Pham J.T., Haeusler A.R., Mistry N.A., Vidensky S., Daley E.L., Poth E.M., Hoover B., Fines D.M., et al. RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense intervention. Neuron. 2013;80:415&#x2013;428. doi: 10.1016/j.neuron.2013.10.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2013.10.015</ArticleId><ArticleId IdType="pmc">PMC4098943</ArticleId><ArticleId IdType="pubmed">24139042</ArticleId></ArticleIdList></Reference><Reference><Citation>Koppers M., Blokhuis A.M., Westeneng H.J., Terpstra M.L., Zundel C.A., Vieira de Sa R., Schellevis R.D., Waite A.J., Blake D.J., Veldink J.H., et al. C9orf72 ablation in mice does not cause motor neuron degeneration or motor deficits. Ann. Neurol. 2015;78:426&#x2013;438. doi: 10.1002/ana.24453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24453</ArticleId><ArticleId IdType="pmc">PMC4744979</ArticleId><ArticleId IdType="pubmed">26044557</ArticleId></ArticleIdList></Reference><Reference><Citation>Burberry A., Suzuki N., Wang J.Y., Moccia R., Mordes D.A., Stewart M.H., Suzuki-Uematsu S., Ghosh S., Singh A., Merkle F.T., et al. Loss-of-function mutations in the C9ORF72 mouse ortholog cause fatal autoimmune disease. Sci. Transl. Med. 2016;8:347ra393. doi: 10.1126/scitranslmed.aaf6038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aaf6038</ArticleId><ArticleId IdType="pmc">PMC5024536</ArticleId><ArticleId IdType="pubmed">27412785</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang J., Zhu Q., Gendron T.F., Saberi S., McAlonis-Downes M., Seelman A., Stauffer J.E., Jafar-Nejad P., Drenner K., Schulte D., et al. Gain of toxicity from ALS/FTD-linked repeat expansions in C9ORF72 Is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs. Neuron. 2016;90:535&#x2013;550. doi: 10.1016/j.neuron.2016.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2016.04.006</ArticleId><ArticleId IdType="pmc">PMC4860075</ArticleId><ArticleId IdType="pubmed">27112497</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Rourke J.G., Bogdanik L., Yanez A., Lall D., Wolf A.J., Muhammad A.K., Ho R., Carmona S., Vit J.P., Zarrow J., et al. C9orf72 is required for proper macrophage and microglial function in mice. Science. 2016;351:1324&#x2013;1329. doi: 10.1126/science.aaf1064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaf1064</ArticleId><ArticleId IdType="pmc">PMC5120541</ArticleId><ArticleId IdType="pubmed">26989253</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudria-Lopez E., Koppers M., de Wit M., van der Meer C., Westeneng H.J., Zundel C.A., Youssef S.A., Harkema L., de Bruin A., Veldink J.H., et al. Full ablation of C9orf72 in mice causes immune system-related pathology and neoplastic events but no motor neuron defects. Acta Neuropathol. 2016;132:145&#x2013;147. doi: 10.1007/s00401-016-1581-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1581-x</ArticleId><ArticleId IdType="pmc">PMC4911370</ArticleId><ArticleId IdType="pubmed">27206760</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters O.M., Cabrera G.T., Tran H., Gendron T.F., McKeon J.E., Metterville J., Weiss A., Wightman N., Salameh J., Kim J., et al. Human C9ORF72 hexanucleotide expansion reproduces RNA foci and dipeptide repeat proteins but not neurodegeneration in BAC transgenic mice. Neuron. 2015;88:902&#x2013;909. doi: 10.1016/j.neuron.2015.11.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2015.11.018</ArticleId><ArticleId IdType="pmc">PMC4828340</ArticleId><ArticleId IdType="pubmed">26637797</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y.B., Chen H.J., Peres J.N., Gomez-Deza J., Attig J., Stalekar M., Troakes C., Nishimura A.L., Scotter E.L., Vance C., et al. Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester RNA binding proteins, and are neurotoxic. Cell Rep. 2013;5:1178&#x2013;1186. doi: 10.1016/j.celrep.2013.10.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2013.10.049</ArticleId><ArticleId IdType="pmc">PMC3898469</ArticleId><ArticleId IdType="pubmed">24290757</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon I., Xiang S., Kato M., Wu L., Theodoropoulos P., Wang T., Kim J., Yun J., Xie Y., McKnight S.L. Poly-dipeptides encoded by the C9orf72 repeats bind nucleoli, impede RNA biogenesis, and kill cells. Science. 2014;345:1139&#x2013;1145. doi: 10.1126/science.1254917.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1254917</ArticleId><ArticleId IdType="pmc">PMC4459787</ArticleId><ArticleId IdType="pubmed">25081482</ArticleId></ArticleIdList></Reference><Reference><Citation>May S., Hornburg D., Schludi M.H., Arzberger T., Rentzsch K., Schwenk B.M., Grasser F.A., Mori K., Kremmer E., Banzhaf-Strathmann J., et al. C9orf72 FTLD/ALS-associated Gly-Ala dipeptide repeat proteins cause neuronal toxicity and Unc119 sequestration. Acta Neuropathol. 2014;128:485&#x2013;503. doi: 10.1007/s00401-014-1329-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-014-1329-4</ArticleId><ArticleId IdType="pmc">PMC4159571</ArticleId><ArticleId IdType="pubmed">25120191</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizielinska S., Gronke S., Niccoli T., Ridler C.E., Clayton E.L., Devoy A., Moens T., Norona F.E., Woollacott I.O.C., Pietrzyk J., et al. C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science. 2014;345:1192&#x2013;1194. doi: 10.1126/science.1256800.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1256800</ArticleId><ArticleId IdType="pmc">PMC4944841</ArticleId><ArticleId IdType="pubmed">25103406</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen X., Tan W., Westergard T., Krishnamurthy K., Markandaiah S.S., Shi Y., Lin S., Shneider N.A., Monaghan J., Pandey U.B., et al. Antisense proline-arginine RAN dipeptides linked to C9ORF72-ALS/FTD form toxic nuclear aggregates that initiate in vitro and in vivo neuronal death. Neuron. 2014;84:1213&#x2013;1225. doi: 10.1016/j.neuron.2014.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2014.12.010</ArticleId><ArticleId IdType="pmc">PMC4632245</ArticleId><ArticleId IdType="pubmed">25521377</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee K.H., Zhang P., Kim H.J., Mitrea D.M., Sarkar M., Freibaum B.D., Cika J., Coughlin M., Messing J., Molliex A., et al. C9orf72 dipeptide repeats impair the assembly, dynamics, and function of membrane-less organelles. Cell. 2016;167:774&#x2013;788 e717. doi: 10.1016/j.cell.2016.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.10.002</ArticleId><ArticleId IdType="pmc">PMC5079111</ArticleId><ArticleId IdType="pubmed">27768896</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y., Mori E., Kato M., Xiang S., Wu L., Kwon I., McKnight S.L. Toxic PR poly-dipeptides encoded by the C9orf72 repeat expansion target LC domain polymers. Cell. 2016;167:789&#x2013;802 e712. doi: 10.1016/j.cell.2016.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2016.10.003</ArticleId><ArticleId IdType="pmc">PMC5076566</ArticleId><ArticleId IdType="pubmed">27768897</ArticleId></ArticleIdList></Reference><Reference><Citation>Hao Z., Liu L., Tao Z., Wang R., Ren H., Sun H., Lin Z., Zhang Z., Mu C., Zhou J., et al. Motor dysfunction and neurodegeneration in a C9orf72 mouse line expressing poly-PR. Nat. Commun. 2019;10:2906. doi: 10.1038/s41467-019-10956-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-10956-w</ArticleId><ArticleId IdType="pmc">PMC6606620</ArticleId><ArticleId IdType="pubmed">31266945</ArticleId></ArticleIdList></Reference><Reference><Citation>Fontecave M., Graslund A., Reichard P. The function of superoxide dismutase during the enzymatic formation of the free radical of ribonucleotide reductase. J. Biol. Chem. 1987;262:12332&#x2013;12336.</Citation><ArticleIdList><ArticleId IdType="pubmed">3040738</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosen D.R., Siddique T., Patterson D., Figlewicz D.A., Sapp P., Hentati A., Donaldson D., Goto J., O&#x2019;Regan J.P., Deng H.X., et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature. 1993;362:59&#x2013;62. doi: 10.1038/362059a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/362059a0</ArticleId><ArticleId IdType="pubmed">8446170</ArticleId></ArticleIdList></Reference><Reference><Citation>Felbecker A., Camu W., Valdmanis P.N., Sperfeld A.D., Waibel S., Steinbach P., Rouleau G.A., Ludolph A.C., Andersen P.M. Four familial ALS pedigrees discordant for two SOD1 mutations: Are all SOD1 mutations pathogenic? J. Neurol. Neurosurg. Psychiatry. 2010;81:572&#x2013;577. doi: 10.1136/jnnp.2009.192310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2009.192310</ArticleId><ArticleId IdType="pubmed">20460594</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita S., Ando Y. Genotype-phenotype relationship in hereditary amyotrophic lateral sclerosis. Transl. NeuroDegener. 2015;4:13. doi: 10.1186/s40035-015-0036-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40035-015-0036-y</ArticleId><ArticleId IdType="pmc">PMC4513711</ArticleId><ArticleId IdType="pubmed">26213621</ArticleId></ArticleIdList></Reference><Reference><Citation>Lattante S., Rouleau G.A., Kabashi E. TARDBP and FUS mutations associated with amyotrophic lateral sclerosis: Summary and update. Hum. Mutat. 2013;34:812&#x2013;826. doi: 10.1002/humu.22319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/humu.22319</ArticleId><ArticleId IdType="pubmed">23559573</ArticleId></ArticleIdList></Reference><Reference><Citation>Hergesheimer R.C., Chami A.A., de Assis D.R., Vourc&#x2019;h P., Andres C.R., Corcia P., Lanznaster D., Blasco H. The debated toxic role of aggregated TDP-43 in amyotrophic lateral sclerosis: A resolution in sight? Brain. 2019;142:1176&#x2013;1194. doi: 10.1093/brain/awz078.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz078</ArticleId><ArticleId IdType="pmc">PMC6487324</ArticleId><ArticleId IdType="pubmed">30938443</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T., Hasegawa M., Akiyama H., Ikeda K., Nonaka T., Mori H., Mann D., Tsuchiya K., Yoshida M., Hashizume Y., et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. BioChem. Biophys. Res. Commun. 2006;351:602&#x2013;611. doi: 10.1016/j.bbrc.2006.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M., Sampathu D.M., Kwong L.K., Truax A.C., Micsenyi M.C., Chou T.T., Bruce J., Schuck T., Grossman M., Clark C.M., et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwiatkowski T.J., Jr., Bosco D.A., Leclerc A.L., Tamrazian E., Vanderburg C.R., Russ C., Davis A., Gilchrist J., Kasarskis E.J., Munsat T., et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science. 2009;323:1205&#x2013;1208. doi: 10.1126/science.1166066.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1166066</ArticleId><ArticleId IdType="pubmed">19251627</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C., Rogelj B., Hortobagyi T., De Vos K.J., Nishimura A.L., Sreedharan J., Hu X., Smith B., Ruddy D., Wright P., et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science. 2009;323:1208&#x2013;1211. doi: 10.1126/science.1165942.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1165942</ArticleId><ArticleId IdType="pmc">PMC4516382</ArticleId><ArticleId IdType="pubmed">19251628</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou Z.Y., Cui L.Y., Sun Q., Li X.G., Liu M.S., Xu Y., Zhou Y., Yang X.Z. De novo FUS gene mutations are associated with juvenile-onset sporadic amyotrophic lateral sclerosis in China. NeuroBiol. Aging. 2013;34:1312.e1&#x2013;1312.e8. doi: 10.1016/j.neurobiolaging.2012.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2012.09.005</ArticleId><ArticleId IdType="pubmed">23046859</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubers A., Just W., Rosenbohm A., Muller K., Marroquin N., Goebel I., Hogel J., Thiele H., Altmuller J., Nurnberg P., et al. De novo FUS mutations are the most frequent genetic cause in early-onset German ALS patients. NeuroBiol. Aging. 2015;36:3117.e1&#x2013;3117.e6. doi: 10.1016/j.neurobiolaging.2015.08.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2015.08.005</ArticleId><ArticleId IdType="pubmed">26362943</ArticleId></ArticleIdList></Reference><Reference><Citation>Gromicho M., Oliveira Santos M., Pinto A., Pronto-Laborinho A., De Carvalho M. Young-onset rapidly progressive ALS associated with heterozygous FUS mutation. Amyotroph. Lateral Scler. Front. Degener. 2017;18:451&#x2013;453. doi: 10.1080/21678421.2017.1299762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1299762</ArticleId><ArticleId IdType="pubmed">28288521</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinszner H., Sok J., Immanuel D., Yin Y., Ron D. TLS (FUS) binds RNA in vivo and engages in nucleo-cytoplasmic shuttling. J. Cell Sci. 1997;110 Pt 15:1741&#x2013;1750.</Citation><ArticleIdList><ArticleId IdType="pubmed">9264461</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu C., Zhang J., Gao F., Yang L., Jia M., Zhu H., Gong W. FUS-NLS/Transportin 1 complex structure provides insights into the nuclear targeting mechanism of FUS and the implications in ALS. PLoS ONE. 2012;7:e47056. doi: 10.1371/journal.pone.0047056.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0047056</ArticleId><ArticleId IdType="pmc">PMC3466232</ArticleId><ArticleId IdType="pubmed">23056579</ArticleId></ArticleIdList></Reference><Reference><Citation>Vance C., Scotter E.L., Nishimura A.L., Troakes C., Mitchell J.C., Kathe C., Urwin H., Manser C., Miller C.C., Hortobagyi T., et al. ALS mutant FUS disrupts nuclear localization and sequesters wild-type FUS within cytoplasmic stress granules. Hum. Mol. Genet. 2013;22:2676&#x2013;2688. doi: 10.1093/hmg/ddt117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt117</ArticleId><ArticleId IdType="pmc">PMC3674807</ArticleId><ArticleId IdType="pubmed">23474818</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaaskelainen O., Solje E., Hall A., Katisko K., Korhonen V., Tiainen M., Kangas A.J., Helisalmi S., Pikkarainen M., Koivisto A., et al. Low serum high-density lipoprotein cholesterol levels associate with the C9orf72 repeat expansion in frontotemporal lobar degeneration patients. J. Alzheimers Dis. 2019;72:127&#x2013;137. doi: 10.3233/JAD-190132.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-190132</ArticleId><ArticleId IdType="pmc">PMC6839456</ArticleId><ArticleId IdType="pubmed">31561355</ArticleId></ArticleIdList></Reference><Reference><Citation>Wuolikainen A., Andersen P.M., Moritz T., Marklund S.L., Antti H. ALS patients with mutations in the SOD1 gene have an unique metabolomic profile in the cerebrospinal fluid compared with ALS patients without mutations. Mol. Genet. Metab. 2012;105:472&#x2013;478. doi: 10.1016/j.ymgme.2011.11.201.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ymgme.2011.11.201</ArticleId><ArticleId IdType="pubmed">22264771</ArticleId></ArticleIdList></Reference><Reference><Citation>Valbuena G.N., Rizzardini M., Cimini S., Siskos A.P., Bendotti C., Cantoni L., Keun H.C. Metabolomic analysis reveals increased aerobic glycolysis and amino acid deficit in a cellular model of amyotrophic lateral sclerosis. Mol. Neurobiol. 2016;53:2222&#x2013;2240. doi: 10.1007/s12035-015-9165-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-015-9165-7</ArticleId><ArticleId IdType="pmc">PMC4823370</ArticleId><ArticleId IdType="pubmed">25963727</ArticleId></ArticleIdList></Reference><Reference><Citation>Valbuena G.N., Tortarolo M., Bendotti C., Cantoni L., Keun H.C. Altered metabolic profiles associate with toxicity in SOD1G93A astrocyte-neuron co-cultures. Sci. Rep. 2017;7:50. doi: 10.1038/s41598-017-00072-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-00072-4</ArticleId><ArticleId IdType="pmc">PMC5428359</ArticleId><ArticleId IdType="pubmed">28246392</ArticleId></ArticleIdList></Reference><Reference><Citation>Patin F., Corcia P., Vourc&#x2019;h P., Nadal-Desbarats L., Baranek T., Goossens J.F., Marouillat S., Dessein A.F., Descat A., Madji Hounoum B., et al. Omics to explore amyotrophic lateral sclerosis evolution: The central role of arginine and proline metabolism. Mol. Neurobiol. 2017;54:5361&#x2013;5374. doi: 10.1007/s12035-016-0078-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-016-0078-x</ArticleId><ArticleId IdType="pubmed">27590138</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzo E., O&#x2019;Conner A.G., Barrows J.M., Shreiner D.D., Birchak G.J., Zarnescu D.C. Medium-chain fatty acids, beta-hydroxybutyric acid and genetic modulation of the carnitine shuttle are protective in a drosophila model of ALS based on TDP-43. Front. Mol. NeuroSci. 2018;11:182. doi: 10.3389/fnmol.2018.00182.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2018.00182</ArticleId><ArticleId IdType="pmc">PMC5990617</ArticleId><ArticleId IdType="pubmed">29904341</ArticleId></ArticleIdList></Reference><Reference><Citation>Manzo E., Lorenzini I., Barrameda D., O&#x2019;Conner A.G., Barrows J.M., Starr A., Kovalik T., Rabichow B.E., Lehmkuhl E.M., Shreiner D.D., et al. Glycolysis upregulation is neuroprotective as a compensatory mechanism in ALS. Elife. 2019;8 doi: 10.7554/eLife.45114.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.45114</ArticleId><ArticleId IdType="pmc">PMC6557627</ArticleId><ArticleId IdType="pubmed">31180318</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanznaster D., Bourgeais J., Bruno C., Hergesheimer R.C., Thepault R.A., Vourc&#x2019;h P., Corcia P., Andres C.R., Herault O., Blasco H. TDP-43-mediated toxicity in HEK293T Cells: A fast and reproducible protocol to be employed in the search of new therapeutic options against amyotrophic lateral sclerosis. Cells. 2019;9:68. doi: 10.3390/cells9010068.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells9010068</ArticleId><ArticleId IdType="pmc">PMC7016571</ArticleId><ArticleId IdType="pubmed">31888078</ArticleId></ArticleIdList></Reference><Reference><Citation>Drepper C., Herrmann T., Wessig C., Beck M., Sendtner M. C-terminal FUS/TLS mutations in familial and sporadic ALS in Germany. NeuroBiol. Aging. 2011;32:548.e1&#x2013;548.e4. doi: 10.1016/j.neurobiolaging.2009.11.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.11.017</ArticleId><ArticleId IdType="pubmed">20018407</ArticleId></ArticleIdList></Reference><Reference><Citation>Chio A., Restagno G., Brunetti M., Ossola I., Calvo A., Mora G., Sabatelli M., Monsurro M.R., Battistini S., Mandrioli J., et al. Two Italian kindreds with familial amyotrophic lateral sclerosis due to FUS mutation. NeuroBiol. Aging. 2009;30:1272&#x2013;1275. doi: 10.1016/j.neurobiolaging.2009.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2009.05.001</ArticleId><ArticleId IdType="pmc">PMC2771748</ArticleId><ArticleId IdType="pubmed">19450904</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandoorne T., Veys K., Guo W., Sicart A., Vints K., Swijsen A., Moisse M., Eelen G., Gounko N.V., Fumagalli L., et al. Differentiation but not ALS mutations in FUS rewires motor neuron metabolism. Nat. Commun. 2019;10:4147. doi: 10.1038/s41467-019-12099-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-019-12099-4</ArticleId><ArticleId IdType="pmc">PMC6742665</ArticleId><ArticleId IdType="pubmed">31515480</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang L., Lv X., Du H., Wu D., Wang M. Causal effects of serum metabolites on amyotrophic lateral sclerosis: A Mendelian randomization study. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2020;97:109771. doi: 10.1016/j.pnpbp.2019.109771.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pnpbp.2019.109771</ArticleId><ArticleId IdType="pubmed">31669200</ArticleId></ArticleIdList></Reference><Reference><Citation>Menni C., Zierer J., Valdes A.M., Spector T.D. Mixing omics: Combining genetics and metabolomics to study rheumatic diseases. Nat. Rev. Rheumatol. 2017;13:174&#x2013;181. doi: 10.1038/nrrheum.2017.5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2017.5</ArticleId><ArticleId IdType="pubmed">28148918</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Wang T., Ji Y.J., Johnson K., Liu H., Johnson K., Bailey S., Suk Y., Lu Y.N., Liu M., et al. A C9orf72-CARM1 axis regulates lipid metabolism under glucose starvation-induced nutrient stress. Genes Dev. 2018;32:1380&#x2013;1397. doi: 10.1101/gad.315564.118.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.315564.118</ArticleId><ArticleId IdType="pmc">PMC6217731</ArticleId><ArticleId IdType="pubmed">30366907</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan Q., D&#x2019;Onofrio G., Sancarlo D., Greco A., Yu Z. Potential fluid biomarkers for pathological brain changes in Alzheimer&#x2019;s disease: Implication for the screening of cognitive frailty. Mol. Med. Rep. 2016;14:3184&#x2013;3198. doi: 10.3892/mmr.2016.5618.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/mmr.2016.5618</ArticleId><ArticleId IdType="pmc">PMC5042792</ArticleId><ArticleId IdType="pubmed">27511317</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S.H., Yang J.S., Lee J.C., Lee J.Y., Lee J.Y., Kim E., Moon M.H. Lipidomic alterations in lipoproteins of patients with mild cognitive impairment and Alzheimer&#x2019;s disease by asymmetrical flow field-flow fractionation and nanoflow ultrahigh performance liquid chromatography-tandem mass spectrometry. J. Chromatogr. A. 2018;1568:91&#x2013;100. doi: 10.1016/j.chroma.2018.07.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chroma.2018.07.018</ArticleId><ArticleId IdType="pubmed">30007793</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa A.C., Joaquim H.P.G., Forlenza O., Talib L.L., Gattaz W.F. Plasma lipids metabolism in mild cognitive impairment and Alzheimer&#x2019;s disease. World J. Biol. Psychiatry. 2019;20:190&#x2013;196. doi: 10.1080/15622975.2017.1369566.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15622975.2017.1369566</ArticleId><ArticleId IdType="pubmed">28922966</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarrafpour S., Ormseth C., Chiang A., Arakaki X., Harrington M., Fonteh A. Lipid metabolism in late-onset Alzheimer&#x2019;s disease differs from patients presenting with other dementia phenotypes. Int. J. Environ. Res. Public Health. 2019;16:1995. doi: 10.3390/ijerph16111995.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph16111995</ArticleId><ArticleId IdType="pmc">PMC6603882</ArticleId><ArticleId IdType="pubmed">31195602</ArticleId></ArticleIdList></Reference><Reference><Citation>Andersen P.M., Forsgren L., Binzer M., Nilsson P., Ala-Hurula V., Keranen M.L., Bergmark L., Saarinen A., Haltia T., Tarvainen I., et al. Autosomal recessive adult-onset amyotrophic lateral sclerosis associated with homozygosity for Asp90Ala CuZn-superoxide dismutase mutation. A clinical and genealogical study of 36 patients. Brain. 1996;119 Pt 4:1153&#x2013;1172. doi: 10.1093/brain/119.4.1153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/119.4.1153</ArticleId><ArticleId IdType="pubmed">8813280</ArticleId></ArticleIdList></Reference><Reference><Citation>Veyrat-Durebex C., Corcia P., Piver E., Devos D., Dangoumau A., Gouel F., Vourc&#x2019;h P., Emond P., Laumonnier F., Nadal-Desbarats L., et al. Disruption of TCA cycle and glutamate metabolism identified by metabolomics in an in vitro model of amyotrophic lateral sclerosis. Mol. Neurobiol. 2016;53:6910&#x2013;6924. doi: 10.1007/s12035-015-9567-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-015-9567-6</ArticleId><ArticleId IdType="pubmed">26666663</ArticleId></ArticleIdList></Reference><Reference><Citation>Madji Hounoum B., Mavel S., Coque E., Patin F., Vourc&#x2019;h P., Marouillat S., Nadal-Desbarats L., Emond P., Corcia P., Andres C.R., et al. Wildtype motoneurons, ALS-Linked SOD1 mutation and glutamate profoundly modify astrocyte metabolism and lactate shuttling. Glia. 2017;65:592&#x2013;605. doi: 10.1002/glia.23114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/glia.23114</ArticleId><ArticleId IdType="pubmed">28139855</ArticleId></ArticleIdList></Reference><Reference><Citation>Patin F., Baranek T., Vourc&#x2019;h P., Nadal-Desbarats L., Goossens J.F., Marouillat S., Dessein A.F., Descat A., Hounoum B.M., Bruno C., et al. combined metabolomics and transcriptomics approaches to assess the IL-6 blockade as a therapeutic of ALS: Deleterious alteration of lipid metabolism. Neurotherapeutics. 2016;13:905&#x2013;917. doi: 10.1007/s13311-016-0461-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13311-016-0461-3</ArticleId><ArticleId IdType="pmc">PMC5081117</ArticleId><ArticleId IdType="pubmed">27444617</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriques A., Croixmarie V., Bouscary A., Mosbach A., Keime C., Boursier-Neyret C., Walter B., Spedding M., Loeffler J.P. Sphingolipid metabolism is dysregulated at transcriptomic and metabolic levels in the spinal cord of an animal model of amyotrophic lateral sclerosis. Front. Mol. Neurosci. 2017;10:433. doi: 10.3389/fnmol.2017.00433.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnmol.2017.00433</ArticleId><ArticleId IdType="pmc">PMC5758557</ArticleId><ArticleId IdType="pubmed">29354030</ArticleId></ArticleIdList></Reference><Reference><Citation>Valbuena G.N., Cantoni L., Tortarolo M., Bendotti C., Keun H.C. spinal cord metabolic signatures in models of fast- and slow-progressing SOD1G93A amyotrophic lateral sclerosis. Front. Mol. Neurosci. 2019;13:1276. doi: 10.3389/fnins.2019.01276.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2019.01276</ArticleId><ArticleId IdType="pmc">PMC6914819</ArticleId><ArticleId IdType="pubmed">31920474</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasco H., Veyrat-Durebex C., Bocca C., Patin F., Vourc&#x2019;h P., Kouassi Nzoughet J., Lenaers G., Andres C.R., Simard G., Corcia P., et al. Lipidomics reveals cerebrospinal-fluid signatures of ALS. Sci. Rep. 2017;7:17652. doi: 10.1038/s41598-017-17389-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-17389-9</ArticleId><ArticleId IdType="pmc">PMC5732162</ArticleId><ArticleId IdType="pubmed">29247199</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez De Aguilar J.L. Lipid biomarkers for amyotrophic lateral sclerosis. Front. Neurol. 2019;10:284. doi: 10.3389/fneur.2019.00284.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2019.00284</ArticleId><ArticleId IdType="pmc">PMC6458258</ArticleId><ArticleId IdType="pubmed">31019485</ArticleId></ArticleIdList></Reference><Reference><Citation>Dupuis L., Corcia P., Fergani A., Gonzalez De Aguilar J.L., Bonnefont-Rousselot D., Bittar R., Seilhean D., Hauw J.J., Lacomblez L., Loeffler J.P., et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008;70:1004&#x2013;1009. doi: 10.1212/01.wnl.0000285080.70324.27.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/01.wnl.0000285080.70324.27</ArticleId><ArticleId IdType="pubmed">18199832</ArticleId></ArticleIdList></Reference><Reference><Citation>Dedic S.I., Stevic Z., Dedic V., Stojanovic V.R., Milicev M., Lavrnic D. Is hyperlipidemia correlated with longer survival in patients with amyotrophic lateral sclerosis? Neurol. Res. 2012;34:576&#x2013;580. doi: 10.1179/1743132812Y.0000000049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/1743132812Y.0000000049</ArticleId><ArticleId IdType="pubmed">22732100</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K., Hirayama T., Takazawa T., Kawabe K., Iwasaki Y. Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: A cross-sectional study. Intern. Med. 2012;51:1501&#x2013;1508. doi: 10.2169/internalmedicine.51.7465.</Citation><ArticleIdList><ArticleId IdType="doi">10.2169/internalmedicine.51.7465</ArticleId><ArticleId IdType="pubmed">22728481</ArticleId></ArticleIdList></Reference><Reference><Citation>Rafiq M.K., Lee E., Bradburn M., McDermott C.J., Shaw P.J. Effect of lipid profile on prognosis in the patients with amyotrophic lateral sclerosis: Insights from the olesoxime clinical trial. Amyotroph. Lateral Scler. Front. Degener. 2015;16:478&#x2013;484. doi: 10.3109/21678421.2015.1062517.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2015.1062517</ArticleId><ArticleId IdType="pubmed">26161993</ArticleId></ArticleIdList></Reference><Reference><Citation>Delaye J.B., Patin F., Piver E., Bruno C., Vasse M., Vourc&#x2019;h P., Andres C.R., Corcia P., Blasco H. Low IDL-B and high LDL-1 subfraction levels in serum of ALS patients. J. Neurol. Sci. 2017;380:124&#x2013;127. doi: 10.1016/j.jns.2017.07.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2017.07.019</ArticleId><ArticleId IdType="pubmed">28870551</ArticleId></ArticleIdList></Reference><Reference><Citation>Beghi E., Pupillo E., Bonito V., Buzzi P., Caponnetto C., Chio A., Corbo M., Giannini F., Inghilleri M., Bella V.L., et al. Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for ALS. Amyotroph. Lateral Scler. Front. Degener. 2013;14:397&#x2013;405. doi: 10.3109/21678421.2013.764568.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2013.764568</ArticleId><ArticleId IdType="pubmed">23421600</ArticleId></ArticleIdList></Reference><Reference><Citation>Gieger C., Geistlinger L., Altmaier E., Hrabe de Angelis M., Kronenberg F., Meitinger T., Mewes H.W., Wichmann H.E., Weinberger K.M., Adamski J., et al. Genetics meets metabolomics: A genome-wide association study of metabolite profiles in human serum. PLoS Genet. 2008;4:e1000282. doi: 10.1371/journal.pgen.1000282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1000282</ArticleId><ArticleId IdType="pmc">PMC2581785</ArticleId><ArticleId IdType="pubmed">19043545</ArticleId></ArticleIdList></Reference><Reference><Citation>Suhre K., Shin S.Y., Petersen A.K., Mohney R.P., Meredith D., Wagele B., Altmaier E., CardioGram, Deloukas P., Erdmann J., et al. Human metabolic individuality in biomedical and pharmaceutical research. Nature. 2011;477:54&#x2013;60. doi: 10.1038/nature10354.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature10354</ArticleId><ArticleId IdType="pmc">PMC3832838</ArticleId><ArticleId IdType="pubmed">21886157</ArticleId></ArticleIdList></Reference><Reference><Citation>Kettunen J., Tukiainen T., Sarin A.P., Ortega-Alonso A., Tikkanen E., Lyytikainen L.P., Kangas A.J., Soininen P., Wurtz P., Silander K., et al. Genome-wide association study identifies multiple loci influencing human serum metabolite levels. Nat. Genet. 2012;44:269&#x2013;276. doi: 10.1038/ng.1073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.1073</ArticleId><ArticleId IdType="pmc">PMC3605033</ArticleId><ArticleId IdType="pubmed">22286219</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin S.Y., Fauman E.B., Petersen A.K., Krumsiek J., Santos R., Huang J., Arnold M., Erte I., Forgetta V., Yang T.P., et al. An atlas of genetic influences on human blood metabolites. Nat. Genet. 2014;46:543&#x2013;550. doi: 10.1038/ng.2982.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng.2982</ArticleId><ArticleId IdType="pmc">PMC4064254</ArticleId><ArticleId IdType="pubmed">24816252</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellin M., Marchetto M.C., Gage F.H., Mummery C.L. Induced pluripotent stem cells: The new patient? Nat. Rev. Mol. Cell Biol. 2012;13:713&#x2013;726. doi: 10.1038/nrm3448.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrm3448</ArticleId><ArticleId IdType="pubmed">23034453</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar D., Anand T., Kues W.A. Clinical potential of human-induced pluripotent stem cells: Perspectives of induced pluripotent stem cells. Cell Biol. Toxicol. 2017;33:99&#x2013;112. doi: 10.1007/s10565-016-9370-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10565-016-9370-9</ArticleId><ArticleId IdType="pubmed">27900567</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaignerie A., Lefort N., Rousselle M., Forest-Choquet V., Flippe L., Francois-Campion V., Girardeau A., Caillaud A., Chariau C., Francheteau Q., et al. Urine-derived cells provide a readily accessible cell type for feeder-free mRNA reprogramming. Sci. Rep. 2018;8:14363. doi: 10.1038/s41598-018-32645-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-32645-2</ArticleId><ArticleId IdType="pmc">PMC6156222</ArticleId><ArticleId IdType="pubmed">30254308</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkhardt M.F., Martinez F.J., Wright S., Ramos C., Volfson D., Mason M., Garnes J., Dang V., Lievers J., Shoukat-Mumtaz U., et al. A cellular model for sporadic ALS using patient-derived induced pluripotent stem cells. Mol. Cell NeuroSci. 2013;56:355&#x2013;364. doi: 10.1016/j.mcn.2013.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2013.07.007</ArticleId><ArticleId IdType="pmc">PMC4772428</ArticleId><ArticleId IdType="pubmed">23891805</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohl D., Pochet R., Mitrecic D., Nicaise C. Modelling and treating amyotrophic lateral sclerosis through induced-pluripotent stem cells technology. Curr. Stem Cell Res. Ther. 2016;11:301&#x2013;312. doi: 10.2174/1574888X10666150528144303.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1574888X10666150528144303</ArticleId><ArticleId IdType="pubmed">26018231</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujimori K., Ishikawa M., Otomo A., Atsuta N., Nakamura R., Akiyama T., Hadano S., Aoki M., Saya H., Sobue G., et al. Modeling sporadic ALS in iPSC-derived motor neurons identifies a potential therapeutic agent. Nat. Med. 2018;24:1579&#x2013;1589. doi: 10.1038/s41591-018-0140-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-018-0140-5</ArticleId><ArticleId IdType="pubmed">30127392</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun X., Song J., Huang H., Chen H., Qian K. Modeling hallmark pathology using motor neurons derived from the family and sporadic amyotrophic lateral sclerosis patient-specific iPS cells. Stem Cell Res. Ther. 2018;9:315. doi: 10.1186/s13287-018-1048-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13287-018-1048-1</ArticleId><ArticleId IdType="pmc">PMC6238404</ArticleId><ArticleId IdType="pubmed">30442180</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen S.P., Hall B., Castelli L.M., Francis L., Woof R., Siskos A.P., Kouloura E., Gray E., Thompson A.G., Talbot K., et al. Astrocyte adenosine deaminase loss increases motor neuron toxicity in amyotrophic lateral sclerosis. Brain. 2019;142:586&#x2013;605. doi: 10.1093/brain/awy353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awy353</ArticleId><ArticleId IdType="pmc">PMC6391613</ArticleId><ArticleId IdType="pubmed">30698736</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen S.P., Hall B., Woof R., Francis L., Gatto N., Shaw A.C., Myszczynska M., Hemingway J., Coldicott I., Willcock A., et al. C9orf72 expansion within astrocytes reduces metabolic flexibility in amyotrophic lateral sclerosis. Brain. 2019;142:3771&#x2013;3790. doi: 10.1093/brain/awz302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz302</ArticleId><ArticleId IdType="pmc">PMC6906594</ArticleId><ArticleId IdType="pubmed">31647549</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawton K.A., Brown M.V., Alexander D., Li Z., Wulff J.E., Lawson R., Jaffa M., Milburn M.V., Ryals J.A., Bowser R., et al. Plasma metabolomic biomarker panel to distinguish patients with amyotrophic lateral sclerosis from disease mimics. Amyotroph. Lateral Scler. Front. Degener. 2014;15:362&#x2013;370. doi: 10.3109/21678421.2014.908311.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.908311</ArticleId><ArticleId IdType="pubmed">24984169</ArticleId></ArticleIdList></Reference><Reference><Citation>Kori M., Aydin B., Unal S., Arga K.Y., Kazan D. Metabolic biomarkers and neurodegeneration: A pathway enrichment analysis of Alzheimer&#x2019;s disease, Parkinson&#x2019;s disease, and amyotrophic lateral sclerosis. Omics. 2016;20:645&#x2013;661. doi: 10.1089/omi.2016.0106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/omi.2016.0106</ArticleId><ArticleId IdType="pubmed">27828769</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X., Ng S.Y., Chia N.S., Acharyya S., Setiawan F., Lu Z.H., Ng E., Tay K.Y., Au W.L., Tan E.K., et al. Serum uric acid level and its association with motor subtypes and non-motor symptoms in early Parkinson&#x2019;s disease: PALS study. Park. Relat. Disord. 2018;55:50&#x2013;54. doi: 10.1016/j.parkreldis.2018.05.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.parkreldis.2018.05.010</ArticleId><ArticleId IdType="pubmed">29779681</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornevik K., Zhang Z., O&#x2019;Reilly E.J., Berry J.D., Clish C.B., Deik A., Jeanfavre S., Kato I., Kelly R.S., Kolonel L.N., et al. Prediagnostic plasma metabolomics and the risk of amyotrophic lateral sclerosis. Neurology. 2019;92:e2089&#x2013;e2100. doi: 10.1212/WNL.0000000000007401.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0000000000007401</ArticleId><ArticleId IdType="pmc">PMC6512888</ArticleId><ArticleId IdType="pubmed">30926684</ArticleId></ArticleIdList></Reference><Reference><Citation>Corey-Bloom J., Haque A., Aboufadel S., Snell C., Fischer R.S., Granger S.W., Granger D.A., Thomas E.A. Uric acid as a potential peripheral biomarker for disease features in Huntington&#x2019;s patients. Front. Mol. Neurosci. 2020;14:73. doi: 10.3389/fnins.2020.00073.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2020.00073</ArticleId><ArticleId IdType="pmc">PMC7065265</ArticleId><ArticleId IdType="pubmed">32194366</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F., Zhang Q., Ke Y., Hao J., Lu L., Lu N., Chen X. Serum uric acid levels in patients with amyotrophic lateral sclerosis: A meta-analysis. Sci. Rep. 2018;8:1100. doi: 10.1038/s41598-018-19609-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-19609-2</ArticleId><ArticleId IdType="pmc">PMC5773600</ArticleId><ArticleId IdType="pubmed">29348425</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakshi R., Xu Y., Mueller K.A., Chen X., Granucci E., Paganoni S., Sadri-Vakili G., Schwarzschild M.A. Urate mitigates oxidative stress and motor neuron toxicity of astrocytes derived from ALS-linked SOD1G93A mutant mice. Mol. Cell. Neurosci. 2018;92:12&#x2013;16. doi: 10.1016/j.mcn.2018.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mcn.2018.06.002</ArticleId><ArticleId IdType="pubmed">29928993</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C., Yang Y., Liang W., Wang T., Wang S., Wang X., Wang Y., Jiang H., Feng H. Neuroprotection by urate on the mutant hSOD1-related cellular and Drosophila models of amyotrophic lateral sclerosis: Implication for GSH synthesis via activating Akt/GSK3beta/Nrf2/GCLC pathways. Brain Res. Bull. 2019;146:287&#x2013;301. doi: 10.1016/j.brainresbull.2019.01.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainresbull.2019.01.019</ArticleId><ArticleId IdType="pubmed">30690059</ArticleId></ArticleIdList></Reference><Reference><Citation>Keizman D., Ish-Shalom M., Berliner S., Maimon N., Vered Y., Artamonov I., Tsehori J., Nefussy B., Drory V.E. Low uric acid levels in serum of patients with ALS: Further evidence for oxidative stress? J. Neurol. Sci. 2009;285:95&#x2013;99. doi: 10.1016/j.jns.2009.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2009.06.002</ArticleId><ArticleId IdType="pubmed">19552925</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagase M., Yamamoto Y., Miyazaki Y., Yoshino H. Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration. Redox Rep. 2016;21:104&#x2013;112. doi: 10.1179/1351000215Y.0000000026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1179/1351000215Y.0000000026</ArticleId><ArticleId IdType="pmc">PMC6837462</ArticleId><ArticleId IdType="pubmed">26191780</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Bai Z., Qin X., Cheng Y. Aberrations in oxidative stress markers in amyotrophic lateral sclerosis: A systematic review and meta-analysis. Oxidative Med. Cell. Longev. 2019;2019:1712323. doi: 10.1155/2019/1712323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2019/1712323</ArticleId><ArticleId IdType="pmc">PMC6590548</ArticleId><ArticleId IdType="pubmed">31281567</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson K., Chan J., Macklin E.A., Levine-Weinberg M., Breen C., Bakshi R., Grasso D.L., Wills A.M., Jahandideh S., Taylor A.A., et al. Pilot trial of inosine to elevate urate levels in amyotrophic lateral sclerosis. Ann. Clin. Transl. Neurol. 2018;5:1522&#x2013;1533. doi: 10.1002/acn3.671.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acn3.671</ArticleId><ArticleId IdType="pmc">PMC6292193</ArticleId><ArticleId IdType="pubmed">30564619</ArticleId></ArticleIdList></Reference><Reference><Citation>Lanznaster D., de Assis D.R., Corcia P., Pradat P.F., Blasco H. Metabolomics biomarkers: A strategy toward therapeutics improvement in ALS. Front. Neurol. 2018;9:1126. doi: 10.3389/fneur.2018.01126.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fneur.2018.01126</ArticleId><ArticleId IdType="pmc">PMC6305341</ArticleId><ArticleId IdType="pubmed">30619076</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanner L.B., Goglia A.G., Wei M.H., Sehgal T., Parsons L.R., Park J.O., White E., Toettcher J.E., Rabinowitz J.D. Four Key Steps Control Glycolytic Flux in Mammalian Cells. Cell Syst. 2018;7:49&#x2013;62 e48. doi: 10.1016/j.cels.2018.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cels.2018.06.003</ArticleId><ArticleId IdType="pmc">PMC6062487</ArticleId><ArticleId IdType="pubmed">29960885</ArticleId></ArticleIdList></Reference><Reference><Citation>Laiko V.V., Baldwin M.A., Burlingame A.L. Atmospheric pressure matrix-assisted laser desorption/ionization mass spectrometry. Anal. Chem. 2000;72:652&#x2013;657. doi: 10.1021/ac990998k.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ac990998k</ArticleId><ArticleId IdType="pubmed">10701247</ArticleId></ArticleIdList></Reference><Reference><Citation>Emara S., Amer S., Ali A., Abouleila Y., Oga A., Masujima T. Single-cell metabolomics. Adv. Exp. Med. Biol. 2017;965:323&#x2013;343. doi: 10.1007/978-3-319-47656-8_13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-319-47656-8_13</ArticleId><ArticleId IdType="pubmed">28132186</ArticleId></ArticleIdList></Reference><Reference><Citation>Chappell L., Russell A.J.C., Voet T. Single-cell (Multi)omics technologies. Ann. Rev. Genom. Hum. Genet. 2018;19:15&#x2013;41. doi: 10.1146/annurev-genom-091416-035324.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-genom-091416-035324</ArticleId><ArticleId IdType="pubmed">29727584</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi M., Philip M.C., Yang N., Sweedler J.V. Single cell neurometabolomics. ACS Chem. NeuroSci. 2018;9:40&#x2013;50. doi: 10.1021/acschemneuro.7b00304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.7b00304</ArticleId><ArticleId IdType="pmc">PMC5800855</ArticleId><ArticleId IdType="pubmed">28982006</ArticleId></ArticleIdList></Reference><Reference><Citation>Germeys C., Vandoorne T., Bercier V., Van Den Bosch L. Existing and emerging metabolomic tools for ALS research. Genes. 2019;10:1011. doi: 10.3390/genes10121011.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/genes10121011</ArticleId><ArticleId IdType="pmc">PMC6947647</ArticleId><ArticleId IdType="pubmed">31817338</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrestha B. Single-cell metabolomics by mass spectrometry. Methods Mol. Biol. 2020;2064:1&#x2013;8. doi: 10.1007/978-1-4939-9831-9_1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-4939-9831-9_1</ArticleId><ArticleId IdType="pubmed">31565762</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>